We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
176
Rhythm Pharmaceuticals
RYTM
$7.25B
$669K 0.03%
24,890
– –
XRN
177
Chiron Real Estate Inc
XRN
$516M
$653K 0.03%
14,680
– –
LMAT icon
178
LeMaitre Vascular
LMAT
$2.34B
$642K 0.03%
27,150
– –
MTEM
179
DELISTED
Molecular Templates, Inc.
MTEM
$582K 0.02%
9,607
– –
ATNX
180
DELISTED
Athenex, Inc. Common Stock
ATNX
$578K 0.02%
2,277
– –
MRTX
181
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$576K 0.02%
13,590
– –
CYH icon
182
Community Health Systems
CYH
$391M
$575K 0.02%
203,935
– –
CNCE
183
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$569K 0.02%
45,362
-45,362
-50% -$626K
A icon
184
Agilent Technologies
A
$39.2B
$553K 0.02%
8,200
-48,600
-86% -$3.27M
ACHN
185
DELISTED
Achillion Pharmaceuticals
ACHN
$507K 0.02%
318,833
-145,928
-31% -$413K
LXRX icon
186
Lexicon Pharmaceuticals
LXRX
$1.04B
$465K 0.02%
70,000
– –
VKTX icon
187
Viking Therapeutics
VKTX
$3.84B
$436K 0.02%
+57,008
New +$682K
ONCE
188
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$422K 0.02%
10,772
-11,274
-51% -$489K
EIDX
189
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$384K 0.02%
27,900
– –
ARWR icon
190
Arrowhead Research
ARWR
$12.3B
$381K 0.02%
+30,700
New +$420K
CDTX
191
DELISTED
Cidara Therapeutics
CDTX
$373K 0.02%
7,939
– –
CAH icon
192
Cardinal Health
CAH
$53.2B
$281K 0.01%
6,300
– –
ADYX
193
DELISTED
Adynxx Inc
ADYX
$278K 0.01%
24,750
-2,750
-10% -$33.4K
ORKA
194
Oruka Therapeutics
ORKA
$5.9B
$271K 0.01%
3,756
– –
CLSD
195
DELISTED
Clearside Biomedical
CLSD
$177K 0.01%
11,022
+5,511
+100% +$259K
BLCM
196
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$175K 0.01%
6,000
– –
NCNA
197
NuCana
NCNA
$5.24M
$142K 0.01%
2
– –
QHC
198
DELISTED
Quorum Health Corporation
QHC
$69K ﹤0.01%
23,725
– –
JNCE
199
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$34K ﹤0.01%
10,127
– –
CLDX icon
200
Celldex Therapeutics
CLDX
$3.02B
$21K ﹤0.01%
7,053
– –
5 6 7
8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.